Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Glaucoma: HELP
Articles by Nicola Pescosolido
Based on 11 articles published since 2010
(Why 11 articles?)

Between 2010 and 2020, N. Pescosolido wrote the following 11 articles about Glaucoma.
+ Citations + Abstracts
1 Review Modulatory effects of 1,25-dihydroxyvitamin D3 on eye disorders: A critical review. 2017

Nebbioso, Marcella / Buomprisco, Giuseppe / Pascarella, Antonia / Pescosolido, Nicola. ·a Department of Sense Organs , Sapienza University of Rome , Rome , Italy. · b Department of Biology and Biotechnology Charles Darwin , Sapienza University of Rome , Rome , Italy. · c Department of Cardiologic, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences , Sapienza University of Rome , Rome , Italy. ·Crit Rev Food Sci Nutr · Pubmed #26054653.

ABSTRACT: Many studies have shown that the presence of 1,25-dihydroxyvitamin D3 in the eye is able to modulate inflammatory responses. In fact, it has been demonstrated that topical administration of vitamin D3 inhibits Langerhans cells migration from the central cornea, corneal neovascularization, and production of cytokines (i.e., interleukin-1-6-8) in experimental animals. Moreover, both in vitro and in vivo studies have demonstrated that vitamin D is a potent inhibitor of retinal neovascularization. It has been shown that calcitriol, the biologically active form of vitamin D, inhibits angiogenesis both in cultured endothelial cells and in retinas from guinea pigs with retinoblastoma or oxygen-induced ischemic retinopathy. In addition, it seems that this compound is able to prevent the progression from early to neovascular age-related macular degeneration (AMD) and, at the same time, to down-regulate the characteristic inflammatory cascade at the retinal pigment epithelium-choroid interface due to its anti-inflammatory and immunomodulatory capabilities. Furthermore, 1,25-dihydroxyvitamin D3 and its analogue, 2-methylene-19-nor-1,25-dihydroxyvitamin D3, are able to modulate intraocular pressure (IOP) through gene expression. Several studies have suggested a role in glaucoma and diabetic retinopathy therapies for vitamin D3. In conclusion, this review summarizes our current knowledge on the potential use of vitamin D3 in the protection and treatment of ocular diseases in ophthalmology.

2 Review Role of dopaminergic receptors in glaucomatous disease modulation. 2013

Pescosolido, Nicola / Parisi, Francesco / Russo, Paola / Buomprisco, Giuseppe / Nebbioso, Marcella. ·Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, 00161 Rome, Italy. ·Biomed Res Int · Pubmed #23878797.

ABSTRACT: Both studies on animals and humans suggest the presence of dopamine (DA) receptors in the anterior segment of the eye. Their role in the dynamics of intraocular pressure (IOP) is not yet clear. DA2 and DA3 receptors are mainly located on postganglionic sympathetic nerve endings. Their stimulation reduces the release of norepinephrine and suppresses the production of aqueous humor. DA1 receptors seem to be more expressed by the ciliary body and the outflow pathway of aqueous humor. The administration of DA1-selective agonists stimulates the production of aqueous humor, increasing IOP, whereas DA2- and DA3-selective agonists could reduce IOP and, therefore, the risk to develop a glaucoma (GL). GL is a broad spectrum of eye diseases which have in common the damage to the optic nerve and the progressive loss of the visual field. Further studies are desirable to clarify the role of the dopaminergic system and the usefulness of DA2 and DA3 agonists in reducing IOP.

3 Article Oral Administration of Forskolin, Homotaurine, Carnosine, and Folic Acid in Patients with Primary Open Angle Glaucoma: Changes in Intraocular Pressure, Pattern Electroretinogram Amplitude, and Foveal Sensitivity. 2016

Mutolo, Maria Giulia / Albanese, Giuseppe / Rusciano, Dario / Pescosolido, Nicola. ·1 Faculty of Medicine and Dentistry, Azienda Ospedaliera Sant'Andrea, Rome University La Sapienza , Rome, Italy . · 2 Faculty of Medicine and Dentistry, Policlinic Umberto I, Rome University La Sapienza , Rome, Italy . · 3 Sooft Italia SpA , Rome, Italy . ·J Ocul Pharmacol Ther · Pubmed #26771282.

ABSTRACT: PURPOSE: To evaluate the effects of a food supplement containing forskolin, homotaurine, carnosine, folic acid, vitamins B1, B2, B6, and magnesium in patients with primary open angle glaucoma (POAG) already in treatment and compensated by intraocular pressure (IOP)-lowering drugs, during a period of 12 months. METHODS: Twenty-two patients (44 eyes) with POAG, with their IOP compensated by topical drugs, were enrolled and randomly assigned to the food supplement or control treatment group. The additional food supplement treatment consisted of 2 tablets per day (1 in the morning, 1 in the evening) given for 1 year of a balanced association of homotaurine, Coleus forskohlii root extract, L-carnosine, folic acid, vitamins B1, B2, B6, and magnesium. Pattern Electroretinogram (PERG) amplitude, foveal sensitivity obtained with the visual field analyzer frequency doubling technology, and IOP were detected at enrollment (T0), 3 months (T1), 6 months (T2), 9 months (T3), and 12 months (T4). RESULTS: We observed in treated patients a significant further decrease of IOP and an improvement of PERG amplitude at 6, 9, and 12 months, and foveal sensitivity at 12 months. All values remained substantially stable in control patients. CONCLUSIONS: The results of the present pilot study indicate that the components of the food supplement reach the eye in a detectable manner, as evidenced by the effects on the IOP. Moreover, they suggest a short-term neuroactive effect, as indicated by the improvement of PERG amplitude and foveal sensitivity in treated, but not in control patients.

4 Article Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients. 2015

Pescosolido, Nicola / Gatto, Vittorio / Stefanucci, Alessio / Rusciano, Dario. ·Facoltà di Medicina e Odontoiatria, Università di Roma La Sapienza, Rome, Italy. ·Ophthalmic Physiol Opt · Pubmed #25600174.

ABSTRACT: PURPOSE: Agomelatine is an agonist of melatonin that is used in the treatment of major depressive disorders. It has also shown an ability to decrease IOP in experiment animals and in normal human subjects. This pilot study addresses for the first time agomelatine effects on the IOP of patients affected by POAG. METHODS: Ten patients affected by hypertensive POAG treated by multiple hypotensive topical drugs and under further treatment with agomelatine (25 mg day(-1) per os) for psychiatric problems, were enrolled. IOP tonometric values were measured at enrolment and after 15 and 30 days of agomelatine supplementation. RESULTS: Agomelatine given orally showed a significant hypotonising effect, stably decreasing IOP by roughly 30% of the enrolment value after 15 and 30 days of treatment. CONCLUSIONS: The hypotonising effect of oral systemic agomelatine at 25 mg day(-1) was able to further decrease IOP in both eyes of all enrolled POAG patients in which multiple drug treatment with anti-glaucoma eye drops had no further effect.

5 Article Iatrogenic dry eye disease: an eledoisin/carnitine and osmolyte drops study. 2013

Nebbioso, Marcella / Evangelista, Mariasilvia / Librando, Aloisa / Plateroti, Andrea Maria / Pescosolido, Nicola. ·Department of Sense Organs, Centre of Ocular Electrophysiology, viale del policlinico 155, 00161 Rome, Italy. Electronic address: marcella.nebbioso@uniroma1.it. ·Biomed Pharmacother · Pubmed #23906760.

ABSTRACT: BACKGROUND: To evaluate the effects of an eye drop containing eledoisin and carnitine in patients suffering from primary open-angle glaucoma (POAG) and ocular discomfort syndrome secondary to a chronically treated with eye drops containing benzalkonium chloride (BAK) as preservative. The dry eye disease was defined as a multifactorial drop disease concerning tears and ocular surface, which brings to discomfort symptoms and visual disorders with potential damage to the ocular surface. Several studies underlined the beneficial effects of secretagogues drugs, such as eledoisin. It is a neuro-peptide extracted from the salivary glands of some shellfishes. Recently, it has been also showed the protective role of carnitine in respect of the ocular surface exposed to the tear film hyperosmolarity. MATERIALS AND METHODS: This randomized double-blind pilot study has been evaluated by lubricant eye drop solutions containing eledoisin and carnitine in 40 patients with ocular discomfort syndrome secondary to POAG, since that the patients were chronically treated with eye drops which decrease eye pressure and contain BAK as preservative. The subjects filled out a questions form concerning the severity of the symptoms and their impact on daily activities. Subsequently Fluorescein Breakup Time (FBUT), Schirmer Test 1 (ST), and Ocular Protection Index (OPI) were measured at baseline and after 15days of treatment. RESULTS: At the end of therapy it was possible to match the beneficial effects of eye drops with carnitin, taurine, sodium hyaluronate and eledoisin. In fact, after 15days of treatment, patients of group 1 showed a decrease of approximately 50% concerning the severity of symptoms and a significant improvement of the tests valued. CONCLUSION: In summary, lubricant eye drops that restore physiological hosmolarity and stimulate tear production represent a promising strategy for dry eye syndrome.

6 Article Forskolin and rutin prevent intraocular pressure spikes after Nd:YAG laser iridotomy. 2012

Nebbioso, M / Belcaro, G / Librando, A / Rusciano, D / Steigerwalt, R D / Pescosolido, N. ·Department of Sense Organs, Centre Ocular Electrophysiology, Sapienza University of Rome, Italy. marcella.nebbioso@uniroma1.it ·Panminerva Med · Pubmed #23241939.

ABSTRACT: AIM: the purpose of this research was to evaluate whether an oral treatment with an association of forskolin and rutin can blunt the intraocular pressure (IOP) spikes and avoid the damage that may occur after laser iridotomy. METHODS: Ten patients underwent bilateral Neodymium:YAG (Nd:YAG) laser iridotomy (Visulas YAG III Laser, Zeiss), for the prevention of primary closed-angle glaucoma. IOP was measured in subjects before and after 7 days of pretreatment with placebo or forskolin and rutin by Goldman applanation tonometry. The IOP was measured before surgery and after surgery at 30-60-120 minutes, and 4-7 days. RESULTS: Analysis of variance indicated a significant increase of the postoperative values in patients receiving treatment with placebo (p < 0.001), but not in those who received treatment with the forskolin and rutin association. T test analysis confirmed that IOP still remained significantly elevated 7 days after laser intervention in placebo treated patients, whereas it stayed within normal values in forskolin/rutin treated patients. CONCLUSION: Forskolin and rutin can blunt the increase of IOP that occurs after Nd-YAG laser iridotomy. This can avoid serious risk to the optic nerve of the patients under laser treatment for iridotomy.

7 Article Oxidative stress in the closed-eyelid test: management of glaucoma. 2012

Pescosolido, N / Malagola, R / Scarsella, G / Lenarduzzi, F / Dapoto, L / Nebbioso, M. ·Department of Cardiovascular, Respiratory, Nephrology and Geriatric Sciences, Sapienza University of Rome, Rome, Italy. marcella.nebbioso@uniroma1.it ·Eur Rev Med Pharmacol Sci · Pubmed #23104665.

ABSTRACT: BACKGROUND AND OBJECTIVES: To evaluate the role of antioxidant drugs in the tonometric increase that follows the closed eyelid test (CET), a predicitive test for glaucoma, after administration of antioxidant substances was observed. MATERIALS AND METHODS: 30 subjects of 54.57+/=5.62 years, 13 males and 17 females, were examined by measuring the ocular pressure after 1 hour from the CET, both in normal conditions and after the administration of antioxidants such as: vitamin A (50,000 IU/die), vitamin E (600 mg/die), and vitamin C (1000 mg/die). The increases in temperature of the iridocorneal angle and of the iris were also measured in the same conditions with an infrared Thermo-Precision tonometer (Sola Electro-Optics, China) both before and after CET. RESULTS: The results showed increased pressure after CET and decreased pressure after the administration of each antioxidant substance, although vitamin A was found to be more effective and with statistically significant values compared to vitamins E and C. CONCLUSIONS: Considering the responses obtained after administration of antioxidant drugs, the ocular hypertension induced after CET could be a response to mixed stress, oxidative and thermic, with degenerative effects on the trabecular meshwork (TM). Besides, in light of these considerations the research results underline that the open angle glaucoma (OAG) should be considered a multifactorial degenerative disease.

8 Article Fixed topical combinations in glaucomatous patients and ocular discomfort. 2012

Nebbioso, Marcella / Evangelista, Mariasilvia / Librando, Aloisa / Di Blasio, Dario / Pescosolido, Nicola. ·Sapienza University of Rome, Centre of Ocular Electrophysiology, Department of Sense Organs, viale del policlinico 155, 00161 Rome, Italy. marcella.nebbioso@uniroma1.it ·Expert Opin Pharmacother · Pubmed #22770575.

ABSTRACT: OBJECTIVE: The purpose of this study was to verify the ocular comfort of a fixed topical combination of brinzolamide 1% plus timolol 0.5% suspension vs. dorzolamide 2% plus timolol 0.5% solution, both preserved with benzalkonium chloride (BAK), in patients with primary open-angle glaucoma (POAG) through subjective and objective methods. BAK is the most commonly used preservative in topical glaucoma medications. METHODS: 62 subjects were examined and included in the analysis. Each patient was asked to complete a questionnaire on symptoms (Ocular Surface Disease Index) and then underwent a series of examinations. The Ocular Protection Index evaluated the risk of damage to the ocular surface, and was expressed as the ratio between fluorescein breakup time and blinking interval. These and other analyses were repeated 30 days after instillation of the new eye drop treatment. RESULTS: The results demonstrated that patients enrolled with the preserved fixed combination of dorzolamide or brinzolamide represented a subgroup of patients in which the discomfort symptoms were supposedly justified by the presence of BAK used chronically in antihypertensive drops. Ocular discomfort scores were significantly higher with dorzolamide/timolol than brinzolamide/timolol (p < 0.0001). CONCLUSIONS: This work shows the better tolerability of brinzolamide 1% plus timolol 0.5% suspension, compared with dorzolamide 2% plus timolol 0.5% solution. Fortunately, some of the adverse reactions induced by preserved eye drop glaucoma medication are reversible after removing the preservatives. Both the potential for added benefit and patient compliance should be considered when selecting ocular hypotensive therapy.

9 Article Trabecular meshwork in normal and pathological eyes. 2012

Pescosolido, Nicola / Cavallotti, Carlo / Rusciano, Dario / Nebbioso, Marcella. ·Department of Science Cardiovascular Respiratory and Morphological Sciences, Sapienza University of Rome, Rome, Italy. ·Ultrastruct Pathol · Pubmed #22471432.

ABSTRACT: PURPOSE: The impact of glycosaminoglycans on intraocular pressure in glaucoma patients and in healthy young or aging subjects is explored. MATERIALS AND METHODS: Thirty small autoptic samples were harvested from the tissue localized around the iridocorneal angle of the eye, taking care not to cause aesthetic damage. The samples came from three groups (young, old, and subjects with glaucoma). All samples were divided in two fragments and both were used for morphological and biochemical analyses. Quantitative data were obtained from image analysis to correlate with biochemical values. All results were statistically analyzed. RESULTS: The findings show the following changes of iridocorneal angle are caused by glycosaminoglycans both in aging and in glacoumatous patients: (1) deposition of fibrous granular material and increased electron density of the structures close to the iridocorneal angle; and (2) strong decrease of hyaluronic acid content and increase of sulfated glycosaminoglycans. CONCLUSIONS: Similar to what happens in other tissues in the body, glycosaminoglycans of the human iridocorneal angle undergo physiological and pathological changes. The trabecular meshwork is the structure responsible for the regulation of the aqueous humor outflow that is often altered in primary open-angle glaucoma patients.

10 Article Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study. 2011

Pescosolido, Nicola / Librando, Aloisa / Puzzono, Marta / Nebbioso, Marcella. ·Department of Cardiovascular, Respiratory, Nephrology and Geriatric Sciences, Centre Glaucoma and Ocular Electrophysiology, Sapienza University of Rome, Rome, Italy. ·J Ocul Pharmacol Ther · Pubmed #21830944.

ABSTRACT: PURPOSE: The purpose of this article was to evaluate whether the anti-inflammatory agent palmitoylethanolamide (PEA) can counteract the increase of intraocular pressure (IOP) that may occur after neodymium-doped: yttrium aluminum garnet (Nd:YAG) laser iridotomy. METHODS: Fifteen patients underwent bilateral laser iridotomy (Visulas YAG III Laser; Zeiss) for the prevention of primary closed-angle glaucoma. The IOP was measured at the beginning of the study (t-1), after 15 days of pretreatment with placebo or PEA (t0), and at 15, 30, and 120 min after the iridotomy (t1, t2, t3). The pretreatment consisted of 2 tablets of placebo or PEA per day for 15 days. RESULTS: The t-test did not show a significant difference between the preoperative mean values of IOP t-1 and t0 in both the pretreatments. Analysis of variance/Tukey's test pointed out a significant increase of the postoperative IOP values in placebo pretreated patients (P≤0.05), but not in those who were pretreated with PEA. The trend analysis confirmed the significant positive trend in placebo pretreatment. The parallelism test between the 2 regressions showed a significant difference for the slopes (P=0.022) and not for the intercepts (P=0.520). CONCLUSIONS: PEA can counteract the increase of IOP that occurs after iridotomy. It is likely that PEA controls the inflammatory process after iridotomy.

11 Article Oral administration of an association of forskolin, rutin and vitamins B1 and B2 potentiates the hypotonising effects of pharmacological treatments in POAG patients. 2010

Pescosolido, N / Librando, A. ·Ophthalmology Department of the University Clinic Umberto I, Sapienza University, Rome, Italy. pescosol@tiscali.it ·Clin Ter · Pubmed #20589347.

ABSTRACT: BACKGROUND/AIMS: Control of intraocular pressure is still the main strategy to treat glaucoma patients. Forskolin has already shown an ability to control intraocular pressure after topic administration, whereas rutin is known to improve ocular blood fl ow. Therefore, aim of this pilot study has been to observe whether administration of an association of oral forskolin and rutin to POAG patients under different regimens of medical therapy may contribute to their effects, further decreasing IOP values. MATERIALS AND METHODS: Forskolin (a natural compound present in the crude extract of the plant Coleus Forskohlii) and rutin are the main ingredients of a food supplement commercially available in Italy. In an open label pilot study, 16 patients with POAG under treatment with different topical drugs and with stable IOP were given additional treatment with the food supplement for 40 days, and their IOP values measured at enrolment, at the end of treatment and 40 days after treatment interruption. RESULTS: Further addition of forskolin and rutin to topical association treatments resulted in a further decrease of IOP by roughly 20% of the initial value. The effect was reversible upon suspension of the treatment. CONCLUSIONS: These data show for the fi rst time that forskolin and rutin given through the oral route appear to reach the ocular district, where they can act in synergy with topical pharmacological treatments, and contribute to the control of intraocular pressure.